- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Dai-Ichi Cutter Kogyo K.K. (1716.TO) Japan Nine Months Ended March 31 GROUP 2025 2024 Revenue Y15.20 bln Y15.54 bln Operating Profit Y1.38 bln Y1.88 bln Pretax Profit Y1.48 bln Y2.06 bln Net ...

The operator of the crippled Fukushima Daiichi nuclear power plant says the average daily increase of contaminated water in the year through March was the lowest since the 2011 accident. Tokyo ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Merck and partner Daiichi Sankyo have initiated the global Phase III IDeate-Esophageal01 trial (NCT06644781) analyzing ifinatamab deruxtecan (I-DXd) in patients with advanced or metastatic esophageal ...